Currently Available Treatment Options for Patients With Myelofibrosis

Abdulraheem Yacoub, MD, reviews the current myelofibrosis treatment landscape including the four approved JAK inhibitors - ruxolitinib, fedratinib, pacritinib, and momelotinib - discussing the clinical trial data and indications for each in first-line and second-line settings.

EP: 1.Diagnosis and Risk Stratification of Myelofibrosis

EP: 2.Treatment Goals for Patients With Myelofibrosis

Now Viewing

EP: 3.Currently Available Treatment Options for Patients With Myelofibrosis

EP: 4.Clinical Experiences With Momelotinib for Patients With Myelofibrosis

EP: 5.Defining Severe Anemia in Patients With Myelofibrosis

EP: 6.Future of Myelofibrosis Treatment

Related Videos